AXS-05: A Novel, Oral, Patent-Protected, Investigational NMDA Receptor Antagonist with Multimodal Activity – Global Emerging Insight and Market Forecast Report 2021-2030 – ResearchAndMarkets.com

AXS-05: A Novel, Oral, Patent-Protected, Investigational NMDA Receptor Antagonist with Multimodal Activity – Global Emerging Insight and Market Forecast Report 2021-2030 – ResearchAndMarkets.com




AXS-05: A Novel, Oral, Patent-Protected, Investigational NMDA Receptor Antagonist with Multimodal Activity – Global Emerging Insight and Market Forecast Report 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “AXS-05 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

AXS-05 is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of major depressive disorder and other central nervous system (CNS) disorders.

“AXS-05 – Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets. A detailed picture of the AXS-05 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

AXS-05 consists of a proprietary formulation and dose of dextromethorphan and bupropion and utilizes Axsome’s metabolic inhibition technology. The dextromethorphan component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently approved therapies for major depressive disorder.

AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of MDD as well as Fast Track designations for the treatment of treatment resistant depression and for the treatment of Alzheimer’s disease agitation. It is being developed by Axsome Therapeutics.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around AXS-05.
  • The report contains forecasted sales for AXS-05 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Treatment Resistant Depression.
  • The report also features the SWOT analysis with analyst insights and key findings of AXS-05.

AXS-05 Analytical Perspective

In-depth AXS-05 Market Assessment

This report provides a detailed market assessment of AXS-05 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

AXS-05 Clinical Assessment

The report provides the clinical trials information of AXS-05 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Treatment Resistant Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence AXS-05 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Treatment Resistant Depression are giving market competition to AXS-05 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AXS-05.
  • This in-depth analysis of the forecasted sales data of AXS-05 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AXS-05.

Key Questions Answered

  • WHICH company is developing AXS-05 along with the phase of the clinical study?
  • What is the technology utilized in the development of AXS-05?
  • What is the product type, route of administration and mechanism of action of AXS-05?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AXS-05 development?
  • What are the key designations that have been granted to AXS-05?
  • What is the forecasted market scenario of AXS-05?
  • What is the history of AXS-05 and what is its future?
  • What is the forecasted sales of AXS-05 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to AXS-05?
  • Which are the late-stage emerging therapies under development for the treatment of the Treatment Resistant Depression?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/akvns6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900